Psoriasis is a chronic, inflammatory, immune‐mediated disease of the skin and joints.
Plaque psoriasis is the most common clinical phenotype of psoriasis. Apremilast is an oral …

Background: Apremilast is a new oral drug for the treatment of moderate to severe plaque
psoriasis that reduces inflammation by inhibiting phosphodiesterase 4. Its efficacy and safety …

Introduction: Psoriasis is a chronic inflammatory skin disease characterized by erythematous
plaques on extensor surfaces, scalp, and back. Current therapies for psoriasis are limited by …

Introduction: Apremilast is an oral phosphodiesterase inhibitor, approved for moderate to
severe psoriasis in adults. Despite the advancement in dermatology, and the introduction of …

Apremilast is a small molecule approved for the treatment of plaques psoriasis and adult
psoriatic arthritis. Pivotal studies have demonstrated short and long term efficacy and safety …

Background: Apremilast is an oral phosphodiesterase 4 (PDE4) inhibitor used for the
treatment of moderate to severe psoriasis. Long-term data on the effectiveness and drug …

Introduction Patients with mild-to-moderate plaque psoriasis often experience reduced
quality of life and increased disease burden due to itch or involvement of psoriasis in special …

Apremilast is a phosphodiesterase-4 inhibitor taken orally. Little information about its use in
routine clinical practice is available. We aimed to assess treatment safety and persistence …

Apremilast, an oral phosphodiesterase-4 inhibitor, is approved for use in the management of
psoriasis and psoriatic arthritis. Although its efficacy and safety have been well established …

Background/Objective: Patients with moderate plaque psoriasis (ie, 5–10% psoriasis-
involved Body Surface Area [BSA]) often receive no treatment or are undertreated with …